GD2 CAR-T: Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
Diagnosis: Diffuse Intrinsic Pontine Glioma (DIPG) and Spinal Cord Diffuse Midline Glioma (DMG) – H3K27 mutated
POE16-01: A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/ Refractory Solid Tumors or Hematologic Malignancies
Diagnosis: Solid & Central Nervous System (CNS) Tumor, Lymphoma, or Leukemia
PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma
Diagnosis: Medulloblastoma
ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Diagnosis: MET aberration, RET mutations, or AXL aberrations
ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
Diagnosis: Non-disease specific
APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility, Screening, Biology, and Outcome Study
Diagnosis: Neoplasm
APEC1621A: LOXO-101 in patients with tumors harboring actionable NTRK fusions
Diagnosis: Solid Tumors
APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Diagnosis: CNS diagnosis with specific mutation
- APEC1621A: Phase 2 study of LOXO-101 (Larotrectinib) in patients with tumors harboring NTRK fusions
- APEC1621B: Phase 2 study of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR alterations
- APEC1621C: Phase 2 study of Tazemetostat in patients with tumors harboring alterations in EZH2 or members of the SWI/SNF complex
- APEC1621D: Phase 2 study of LY3023414 in patients with solid tumors
- APEC1621E: Phase 2 study of Selumetinib in patients with tumors harboring activating MAPK pathway mutations
- APEC1621F: Phase 2 study of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
- APEC1621G: Phase 2 study of Vemurafenib in patients with tumors harboring BRAF V600 mutations
- APEC1621H: Phase 2 study of Olaparib in patients with tumors harboring defects in DNA damage repair genes
- APEC1621I: Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
- APEC1621J: Phase 2 subprotocol of BVD-523FB (ulixertinib) in patients with tumors harboring activating MAPK Pathway Mutations
UCSC Treehouse: California Initiative to Advance Precision Medicine: California Kids Cancer Comparison, and Treehouse Childhood Cancer Initiative
Diagnosis: All relapsed/refractory solid tumors